MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance
暂无分享,去创建一个
A. Paradiso | A. Vacca | V. Racanelli | M. Mariggiò | V. Desantis | M. Frassanito | I. Saltarella | Antonio Giovanni Solimando | A. Lamanuzzi | A. Melaccio | Aurelia Lamanuzzi | Ilaria Saltarella
[1] K. Kelnar,et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours , 2020, British Journal of Cancer.
[2] Sundeep Kumar,et al. Identification and evolutionary analysis of polycistronic miRNA clusters in domesticated and wild wheat. , 2020, Genomics.
[3] M. Egeblad,et al. Communication in tiny packages: Exosomes as means of tumor-stroma communication. , 2020, Biochimica et biophysica acta. Reviews on cancer.
[4] H. Handa,et al. The Role and Function of microRNA in the Pathogenesis of Multiple Myeloma , 2019, Cancers.
[5] K. Ohyashiki,et al. Induction of multiple myeloma bone marrow stromal cell apoptosis by inhibiting extracellular vesicle miR-10a secretion. , 2019, Blood advances.
[6] H. Einsele,et al. High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment , 2019, Journal of clinical medicine.
[7] J. Kocerha,et al. The Potential for microRNA Therapeutics and Clinical Research , 2019, Front. Genet..
[8] B. Nico,et al. Bone marrow fibroblasts overexpress miR‐27b and miR‐214 in step with multiple myeloma progression, dependent on tumour cell‐derived exosomes , 2019, The Journal of pathology.
[9] S. Bhattacharjee,et al. Combination therapy to checkmate Glioblastoma: clinical challenges and advances , 2018, Clinical and Translational Medicine.
[10] C. Peng,et al. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation , 2018, Front. Endocrinol..
[11] Jing Peng,et al. The expression and role of miR-181a in multiple myeloma , 2018, Medicine.
[12] Behzad Baradaran,et al. Treating cancer with microRNA replacement therapy: A literature review , 2018, Journal of cellular physiology.
[13] Guoan Chen,et al. The diagnostic and prognostic value of plasma microRNA-125b-5p in patients with multiple myeloma. , 2018, Oncology letters.
[14] Carla Oliveira,et al. Anti-miRNA oligonucleotides: A comprehensive guide for design , 2018, RNA biology.
[15] Xi Luo,et al. The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma , 2018, Oncology letters.
[16] Saife Niaz. The AGO proteins: an overview , 2018, Biological chemistry.
[17] G. Reid,et al. Response to "An innovative mesothelioma treatment based on mir-16 mimic loaded EGFR targeted minicells (TargomiRs)". , 2018, Translational lung cancer research.
[18] P. Tassone,et al. Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment , 2017, Scientific Reports.
[19] N. Munshi,et al. MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells , 2017, Leukemia.
[20] Lin Xm,et al. MiR-155 regulates lymphoma cell proliferation and apoptosis through targeting SOCS3/JAK-STAT3 signaling pathway. , 2017 .
[21] S. Baldari,et al. Exosomes and other extracellular vesicles-mediated microRNA delivery for cancer therapy , 2017 .
[22] T. Whiteside,et al. Response Commentary: Exosomes vs microvesicles in hematological malignancies , 2017, Leukemia.
[23] I. Fernandez-Piñeiro,et al. Nanocarriers for microRNA delivery in cancer medicine. , 2017, Biotechnology advances.
[24] J. Fei,et al. Integrative analysis of signaling pathways and diseases associated with the miR-106b/25 cluster and their function study in berberine-induced multiple myeloma cells , 2017, Functional & Integrative Genomics.
[25] O. Elemento,et al. Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell , 2017, Nucleic acids research.
[26] L. Trippa,et al. Prognostic role of circulating exosomal miRNAs in multiple myeloma. , 2017, Blood.
[27] A. Brenner,et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors , 2017, Investigational New Drugs.
[28] F. Slack,et al. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases , 2017, Nature Reviews Drug Discovery.
[29] S. Khan,et al. miRNA nanotherapeutics for cancer. , 2017, Drug discovery today.
[30] John T. Powers,et al. The LIN28B/let-7 axis is a novel therapeutic pathway in Multiple Myeloma , 2016, Leukemia.
[31] B. Nico,et al. Microenvironment drug resistance in multiple myeloma: emerging new players , 2016, Oncotarget.
[32] X. Leleu,et al. Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity. , 2016, Cancer letters.
[33] F. Slack,et al. OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer. , 2016, Cancer research.
[34] Jian Li,et al. MiR-10b decreases sensitivity of glioblastoma cells to radiation by targeting AKT , 2016, Journal of Biological Research-Thessaloniki.
[35] Keunchil Park,et al. MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy. , 2016 .
[36] N. Pavlakis,et al. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. , 2016, Epigenomics.
[37] Meng Chen,et al. Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma , 2016, Oncotarget.
[38] N. Munshi,et al. Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma , 2016, Molecular Cancer Therapeutics.
[39] Saurabh Singh,et al. Nanocarrier-based co-delivery of small molecules and siRNA/miRNA for treatment of cancer. , 2016, Therapeutic delivery.
[40] Jie Tian,et al. Effect of surface properties on liposomal siRNA delivery. , 2016, Biomaterials.
[41] Massimo Fresta,et al. Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma , 2015, Scientific Reports.
[42] G. Calin,et al. PDL1 Regulation by p53 via miR-34 , 2015, Journal of the National Cancer Institute.
[43] N. Munshi,et al. A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells , 2015, Clinical Cancer Research.
[44] Chun-mei Wang,et al. MicroRNA-34c targets TGFB-induced factor homeobox 2, represses cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. , 2015, Oncology letters.
[45] Jian-jun Zhao,et al. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. , 2015, Cancer research.
[46] Won Jong Kim,et al. Simultaneous Drug and Gene Delivery from the Biodegradable Poly(ε-caprolactone) Nanofibers for the Treatment of Liver Cancer. , 2015, Journal of nanoscience and nanotechnology.
[47] K. Anderson,et al. Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo , 2015, Leukemia.
[48] J. Willmann,et al. Ultrasound-guided delivery of microRNA loaded nanoparticles into cancer. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[49] Wei Huang,et al. Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment , 2015, Acta pharmaceutica Sinica. B.
[50] P. Tassone,et al. A p53‐Dependent Tumor Suppressor Network Is Induced by Selective miR‐125a‐5p Inhibition in Multiple Myeloma Cells , 2014, Journal of cellular physiology.
[51] Tao Gong,et al. Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[52] R. Tekade,et al. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[53] T. Jiang,et al. MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras. , 2014, Neuro-oncology.
[54] K. Anderson,et al. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib , 2014, Leukemia.
[55] Mark Ibberson,et al. Endogenous RNAs modulate microRNA sorting to exosomes and transfer to acceptor cells. , 2014, Cell reports.
[56] M. Bushell,et al. The complexity of miRNA-mediated repression , 2014, Cell Death and Differentiation.
[57] P. Tassone,et al. Mir-34: A New Weapon Against Cancer? , 2014, Molecular therapy. Nucleic acids.
[58] L. Pfeffer,et al. MicroRNA-18a inhibits hypoxia-inducible factor 1α activity and lung metastasis in basal breast cancers , 2014, Breast Cancer Research.
[59] Lin He,et al. miR-34a Blocks Osteoporosis and Bone Metastasis by Inhibiting Osteoclastogenesis and Tgif2 , 2014, Nature.
[60] Silvia Catuogno,et al. Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[61] Giuseppina Turturici,et al. Extracellular membrane vesicles as a mechanism of cell-to-cell communication: advantages and disadvantages. , 2014, American journal of physiology. Cell physiology.
[62] E. Anaissie,et al. MicroRNA theragnostics for the clinical management of multiple myeloma , 2014, Leukemia.
[63] F. Camargo,et al. Hippo Signaling Regulates Microprocessor and Links Cell-Density-Dependent miRNA Biogenesis to Cancer , 2014, Cell.
[64] M. Cannataro,et al. In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma , 2014, PloS one.
[65] Christopher J. Cheng,et al. Sustained delivery of proangiogenic microRNA‐132 by nanoparticle transfection improves endothelial cell transplantation , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[66] L. J. Lee,et al. Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[67] Yu Zhang,et al. Progress in microRNA delivery. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[68] B. Moudgil,et al. Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer , 2013, International journal of nanomedicine.
[69] C. Cho,et al. Nanoparticle-mediated delivery of therapeutic genes: focus on miRNA therapeutics , 2013, Expert opinion on drug delivery.
[70] Michael Chopp,et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. , 2013, Cancer letters.
[71] P. Tassone,et al. miR‐29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma‐related bone disease , 2013, Journal of cellular physiology.
[72] L. J. Lee,et al. Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer , 2013, Molecular therapy. Nucleic acids.
[73] D. Scadden,et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. , 2013, The Journal of clinical investigation.
[74] N. Munshi,et al. Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth , 2013, Clinical Cancer Research.
[75] Yu Hu,et al. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. , 2013, Carcinogenesis.
[76] N. Munshi,et al. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 , 2012, Cell Death and Disease.
[77] M. Negrini,et al. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma , 2012, Oncotarget.
[78] P. Tassone,et al. MicroRNAs in the pathobiology of multiple myeloma. , 2012, Current cancer drug targets.
[79] P. Tassone,et al. Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma , 2012, Current cancer drug targets.
[80] J. Sheng,et al. Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy. , 2012, Molecular pharmaceutics.
[81] Christopher J. Cheng,et al. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma , 2012, Proceedings of the National Academy of Sciences.
[82] Nahum Sonenberg,et al. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC , 2012, Nature Structural &Molecular Biology.
[83] E. Kimura,et al. MicroRNA miR-146b-5p regulates signal transduction of TGF-β by repressing SMAD4 in thyroid cancer , 2012, Oncogene.
[84] V. Palanisamy,et al. Horizontal transfer of RNAs: exosomes as mediators of intercellular communication , 2012, Wiley interdisciplinary reviews. RNA.
[85] C. Croce,et al. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review , 2012, EMBO molecular medicine.
[86] L. Benetatos,et al. Deregulated microRNAs in multiple myeloma , 2012, Cancer.
[87] A. Bader,et al. Developing therapeutic microRNAs for cancer , 2011, Gene Therapy.
[88] Yuefeng Yang,et al. Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1. , 2011, Biochemical and biophysical research communications.
[89] Jianyong Li,et al. miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. , 2011, Cancer letters.
[90] Huimin Wang,et al. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation , 2011, Leukemia & lymphoma.
[91] R. Hartmann,et al. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. , 2011, Cancer research.
[92] Bo Yu,et al. MicroRNA delivery by cationic lipoplexes for lung cancer therapy. , 2011, Molecular pharmaceutics.
[93] K. Kelnar,et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. , 2011, Nature medicine.
[94] R. Carrasco,et al. Pathogenesis of myeloma. , 2011, Annual review of pathology.
[95] W. Filipowicz,et al. The widespread regulation of microRNA biogenesis, function and decay , 2010, Nature Reviews Genetics.
[96] Kwan Yeung Wong,et al. Epigenetic Inactivation of the miR-124-1 in Haematological Malignancies , 2010, PloS one.
[97] N. Heerema,et al. MicroRNA Profiles of Drug-Resistant Myeloma Cell Lines , 2010, Acta Haematologica.
[98] Ji Wan,et al. Structure and activity of putative intronic miRNA promoters. , 2010, RNA.
[99] Gabriele Sales,et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. , 2009, Blood.
[100] C. Croce. Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.
[101] Charles P. Lin,et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. , 2009, Blood.
[102] C. Croce,et al. SnapShot: MicroRNAs in Cancer , 2009, Cell.
[103] V. Kim,et al. Regulation of microRNA biogenesis , 2014, Nature Reviews Molecular Cell Biology.
[104] C. Croce,et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis , 2008, Proceedings of the National Academy of Sciences.
[105] F. Slack,et al. let-7 microRNAs in development, stem cells and cancer. , 2008, Trends in molecular medicine.
[106] Dong Wei,et al. Phase I Clinical Trial of Autologous Ascites-derived Exosomes Combined With GM-CSF for Colorectal Cancer , 2008, Molecular Therapy.
[107] D. Iliopoulos,et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. , 2008, Cancer cell.
[108] Jörg Hackermüller,et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. , 2007, Blood.
[109] R. Stallings,et al. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells , 2007, Oncogene.
[110] L. Lim,et al. A microRNA component of the p53 tumour suppressor network , 2007, Nature.
[111] Zhiyuan Hu,et al. A novel PEGylation of chitosan nanoparticles for gene delivery , 2007, Biotechnology and applied biochemistry.
[112] Olivier Lantz,et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial , 2005, Journal of Translational Medicine.
[113] J. Le Pecq,et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer , 2005, Journal of Translational Medicine.
[114] Lin He,et al. MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.
[115] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[116] J. Hecker,et al. Stability of mRNA/cationic lipid lipoplexes in human and rat cerebrospinal fluid: methods and evidence for nonviral mRNA gene delivery to the central nervous system. , 2003, Human gene therapy.
[117] V. Kim,et al. MicroRNA maturation: stepwise processing and subcellular localization , 2002, The EMBO journal.
[118] K. Anwer,et al. Cationic lipid-based delivery system for systemic cancer gene therapy , 2000, Cancer Gene Therapy.
[119] T. Bettinger,et al. Chitosan-Based Vector/DNA Complexes for Gene Delivery: Biophysical Characteristics and Transfection Ability , 1998, Pharmaceutical Research.
[120] M. Scheideler,et al. Lipid Nanocarriers for microRNA Delivery. , 2019, Chemistry and physics of lipids.
[121] Y. Zhang,et al. MicroRNA-92 regulates vascular smooth muscle cell function by targeting KLF4 during vascular restenosis and injury. , 2019, International journal of clinical and experimental pathology.
[122] X-M Li,et al. MiR-155 regulates lymphoma cell proliferation and apoptosis through targeting SOCS3/JAK-STAT3 signaling pathway. , 2017, European review for medical and pharmacological sciences.
[123] Hyundong Yoo,et al. Long chain microRNA conjugates in calcium phosphate nanoparticles for efficient formulation and delivery , 2014, Archives of Pharmacal Research.
[124] R. Mahato,et al. miRNAs in pancreatic cancer: therapeutic potential, delivery challenges and strategies. , 2015, Advanced drug delivery reviews.
[125] Leaf Huang,et al. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. , 2015, Advanced drug delivery reviews.
[126] Zhiguo Wang. The guideline of the design and validation of MiRNA mimics. , 2011, Methods in molecular biology.
[127] J. Costello,et al. Epigenetic inactivation of the miR-34a in hematological malignancies. , 2010, Carcinogenesis.